Patient Commitment

CSL Behring is committed to saving lives and improving the quality of life for patients with rare and serious diseases worldwide. This commitment is reflected in our support of programs and activities for patients with rare diseases including bleeding disorders, primary immune deficiencies and Alpha1-proteinase inhibitor deficiencies. We partner with patient advocacy organizations to promote quality medical care and services and to improve and expand educational and outreach efforts. We work with government authorities to ensure patients have access to care while also funding medical research.

Our patient-focused activities are highlighted in "Policy Impact," CSL Behring's public policy newsletter. We publish two editions of our newsletters specific to geographies in which we operate -- "Policy Impact - United States" and "Policy Impact - European Union."

To help our patients learn more about current legislative initiatives or policies and regulations that impact our patients' lives, we also provide links to articles about blood plasma and recombinant therapies.

Finally, as a global company our public policies extend beyond the boundaries of the United States to Europe and beyond. Through our membership in the European Federation of Pharmaceutical Industries and Associations (EFPIA), CSL Behring is working with the Plasma Protein Therapeutics Association and EFPIA Japan to develop a system that will allow simultaneous new drug submissions in Japan, Europe and the United States.